RXQ Compounding Recalls Ascorbic Acid Injection Due to Crystallization
RXQ Compounding LLC is voluntarily recalling Ascorbic Acid 500 MG/ML Injection due to crystallization. The recall covers all lots within expiry distributed nationwide.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The FDA classified this recall as Class II. According to the severity rubric, FDA Class II recalls are assigned a score of 4 (Severe), particularly when specific defects like crystallization in injectable drugs are involved.
Plain-English summary
RXQ Compounding LLC has initiated a voluntary recall of Ascorbic Acid 500 MG/ML (Non-Corn) Injection (PFV), 50 mL per vial. The recall was initiated on June 19, 2019, and the product is identified by NDC 70731-0173-10.
The reason for the recall is crystallization within the product. The FDA classified this recall as Class II, which indicates a situation that might cause temporary or medically reversible adverse health consequences. The recall covers all lots within their expiration dates.
The product was distributed nationwide in the United States. Consumers and healthcare providers should stop using the recalled product and contact their pharmacist or healthcare provider for further instructions or a replacement.
The recalled product
- Product
- Ascorbic Acid 500 MG/ML (Non-Corn) Injection (PFV), 50 mL per vial, RXQ Compounding, 340 West State Street, Unit 9, Athens, OH 45701. NDC: 70731-0173-10
- Manufacturer
- RXQ Compounding LLC
- Category
- Drug — Injectable
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lots within expiry
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 86 recalled by RXQ Compounding LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 86 products in this recall →Related recalls
Same manufacturer · RXQ Compounding LLC
See all →- HighRXQ Compounding Recalls Niacinamide Vials Due to Sterility Concerns
FDA (Drugs) · 2019-08-14
- SevereRXQ Compounding Recalls Glutathione Injection Due to Sterility Concerns
FDA (Drugs) · 2019-08-14
- SevereFDA Recalls Fentanyl Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2019-08-14
- SevereRXQ Compounding Recalls Methylcobalamin Injectable Solution Due to Sterility Concerns
FDA (Drugs) · 2019-08-14
- SevereRXQ Compounding Recalls Folic Acid Injection Due to Sterility Concerns
FDA (Drugs) · 2019-08-14
Same hazard · crystallization
See all →- ModerateCyproheptadine Hydrochloride Syrup Recall Due to Precipitate
FDA (Drugs) · 2026-07-29
- HighBuprenorphine injection vials show crystallization identified as buprenorphine free base
FDA (Drugs) · 2026-06-24
- ModerateDapsone Gel Recalled Nationwide for Crystallization
FDA (Drugs) · 2025-01-08
- HighDapsone Topical Gel Recalled Due to Crystallization Defect
FDA (Drugs) · 2025-01-08
- ModerateOTC cough and congestion medication recalled for crystallization
FDA (Drugs) · 2024-11-13